Aktieanalys

Ascelia: Q2 following the required re-evaluation of the SPARKLE study - Redeye

Redeye Publicerad: 18 Aug 2023 09:01

The FDA feedback later this year will be very important. If it is enough with a revaluation based on new readers the financial challenge is significant. If FDA asks for a new and modified study Ascelia's financial and clinical challenge is of course even tougher. Secondly we look forward to Ascelia's expected planned mid-September update regarding the timelines and the financial implications by mid-September. The Q2 feedback includes an operating cash burn of SEK 42.3m and a cash balance of SEK 70.5m as of end June.

Länk till analysen i sin helhet: https://www.redeye.se/research/934782/ascelia-q2-following-the-required-re-evaluation-of-the-sparkle-study?utm_source=finwire&utm_medium=RSS

Nyheter om Ascelia Pharma

Läses av andra just nu

Innehåller annonslänkar. Investeringar innebär risk (se här)

Tips: 50% rabatt hos fondroboten Opti

Dags att komma igång med sparande? Fondroboten Opti erbjuder en populär spartjänst som är perfekt för regelbundet månadssparande. Just nu får nya kunder som använder Börskollens unika kampanjkod BORSKOLLEN50 automatiskt 50 % rabatt på Optis avgift i 3 månader!